In the multivariate analysis, standardised KELIM was not significantly associated with survival when tested together with high-risk disease (yes versus no, OR = 0.28, 95% CI 0.08–0.95) and BRCA2 mutation (yes versus no, OR = 1.78, 95% CI 1.46–21.03), suggesting that BRCA2 mutation integrates the information about the tumour’s intrinsic chemosensitivity. The gene discussed is BRCA2; the disease is neoplasm.